{
  "label": "clinical_signal_03_ep_002",
  "artifact_type": "signal_episode",
  "artifact_id": "sha256:6c5ea001e642ce17b999895099ef67f7929adda66690d7a53eaf25da0a81b15e",
  "input_ids": [
    "sha256:b4ba5337b06c8de68ac3315db1a4f6980c5bd48efd529c3914f30297d6afd329",
    "sha256:161174e8025b5c956602ccc4e17b4e677c58230b1b64641f357c400c448b8151"
  ],
  "prompt_id": null,
  "model_config": null,
  "created_at": "2026-02-17T11:54:16.237806",
  "content": "## 2024-03-11 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 60\n- Active: 60\n- Screen Failures Cumulative: 4\n- Withdrawals Cumulative: 0\n\n#### Sites\n- Site 01 Enrolled: 6\n- Site 01 Active: 6\n- Site 01 Statin Concomitant: 1\n- Site 02 Enrolled: 4\n- Site 02 Active: 4\n- Site 02 Statin Concomitant: 1\n- Site 03 Enrolled: 5\n- Site 03 Active: 5\n- Site 03 Statin Concomitant: 1\n- Site 04 Enrolled: 4\n- Site 04 Active: 4\n- Site 04 Statin Concomitant: 1\n- Site 05 Enrolled: 5\n- Site 05 Active: 5\n- Site 05 Statin Concomitant: 1\n- Site 06 Enrolled: 3\n- Site 06 Active: 3\n- Site 06 Statin Concomitant: 1\n- Site 07 Enrolled: 6\n- Site 07 Active: 6\n- Site 07 Statin Concomitant: 1\n- Site 08 Enrolled: 4\n- Site 08 Active: 4\n- Site 08 Statin Concomitant: 1\n- Site 09 Enrolled: 5\n- Site 09 Active: 5\n- Site 09 Statin Concomitant: 1\n- Site 10 Enrolled: 4\n- Site 10 Active: 4\n- Site 10 Statin Concomitant: 1\n- Site 11 Enrolled: 5\n- Site 11 Active: 5\n- Site 11 Statin Concomitant: 1\n- Site 12 Enrolled: 4\n- Site 12 Active: 4\n- Site 12 Statin Concomitant: 1\n\n### Lab Panels\n#### Statin Subgroup\n- N: 53\n- ALT (U/L) Mean: 26.8\n- ALT (U/L) Median: 26.3\n- AST (U/L) Mean: 22.1\n- AST (U/L) Median: 20.8\n- Bilirubin (mg/dL) Mean: 0.73\n- Bilirubin (mg/dL) Median: 0.72\n- ALP (U/L) Mean: 71.0\n- ALP (U/L) Median: 75.0\n- Creatinine (mg/dL) Mean: 0.85\n- Creatinine (mg/dL) Median: 0.93\n- BUN (mg/dL) Mean: 16.6\n- BUN (mg/dL) Median: 16.0\n- WBC (K) Mean: 7.5\n- WBC (K) Median: 7.0\n- Platelets (K) Mean: 236\n- Platelets (K) Median: 249\n\n#### Non-Statin Subgroup\n- N: 122\n- ALT (U/L) Mean: 29.7\n- ALT (U/L) Median: 28.0\n- AST (U/L) Mean: 20.7\n- AST (U/L) Median: 20.0\n- Bilirubin (mg/dL) Mean: 0.9\n- Bilirubin (mg/dL) Median: 0.89\n- ALP (U/L) Mean: 56.7\n- ALP (U/L) Median: 60.5\n- Creatinine (mg/dL) Mean: 0.92\n- Creatinine (mg/dL) Median: 0.82\n- BUN (mg/dL) Mean: 16.0\n- BUN (mg/dL) Median: 13.8\n- WBC (K) Mean: 7.5\n- WBC (K) Median: 6.8\n- Platelets (K) Mean: 233\n- Platelets (K) Median: 220\n\n### Adverse Events\n- AE ID: AE-0005, Description: diarrhea, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0006, Description: nasopharyngitis, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0007, Description: nausea, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 52\n- ACE Inhibitor Count: 27\n- Metformin Count: 23\n- PPI Count: 18\n- NSAID Count: 12\n- Other Count: 35\n\n### Protocol Deviations\n- PD ID: PD-004, Description: IP temperature excursion during shipment, 2h out of range, Severity: moderate, Site: site_02\n- PD ID: PD-005, Description: Dose modification without documented PI approval, Severity: moderate, Site: site_05\n- PD ID: PD-006, Description: Informed consent version outdated by 1 revision, Severity: minor, Site: site_12\n\n### Investigator Notes\n- Site pharmacy inventory verified\n- Subject retention rate within protocol targets\n- Study drug accountability reconciled, no discrepancies\n\n### Events\n- Data management plan revision v2.5 distributed\n- Site 12 pharmacy temperature log reviewed: compliant\n\n### Notes\n- Week 2: Enrollment proceeding per plan. Lab panels within reference ranges. Routine AEs only.",
  "metadata": {
    "episode_id": "clinical_signal_03_ep_002",
    "scope_id": "clinical_signal_03",
    "timestamp": "2024-03-11T10:00:00",
    "phase": "baseline",
    "signal_density": "none",
    "episode_type": "signal",
    "layer_name": "signal_episodes",
    "layer_level": 2,
    "build_fingerprint": {
      "scheme": "synix:build:v1",
      "digest": "724335e48952198659b608a79f591f6985cc457d1b0726c271a193e4d218a284",
      "components": {
        "transform": "f5403588af46952374060f29447e5a7639e5b66fc9aef1799b08473882c4bcbc",
        "inputs": "a94b84fbaca9bd62"
      }
    },
    "transform_fingerprint": {
      "scheme": "synix:transform:v2",
      "digest": "f5403588af46952374060f29447e5a7639e5b66fc9aef1799b08473882c4bcbc",
      "components": {
        "transform_id": "cb4ddfa83a38701b",
        "source": "42e76241d396a578",
        "model": "1e2ccf75e96d7ee7"
      }
    }
  }
}